• Contact Us
  • Careers
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Travere Therapeutics
  • Our Company
    • Who We Are
    • Leadership & Board
    • Patient Advocacy
      • Bridges to Kidney Health
    • Our Culture in Action
    • Grant Programs
      • Advocacy & Charitable Grants
      • ISR Grants
      • Med Ed Grants
    • Contact Us
    • Careers
    • Company News
  • Our Science
    • Our Pipeline
      • Sparsentan for FSGS
      • Pegtibatinase
    • Therapeutic Areas
      • IgA Nephropathy (IgAN)
      • Focal Segmental Glomerulosclerosis (FSGS)
      • Classical Homocystinuria (HCU)
      • Cystinuria
    • Clinical Trials
    • Expanded Access
    • Publications
    • Medical Affairs
  • Our Therapies
  • Rare Life
  • Investors & Media

Travere Therapeutics to Report Third Quarter 2025 Financial Results

View Full Press Release
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025
Travere Therapeutics Reports Third Quarter 2025 Financial Results
↑ Return to Top
Travere logo
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • Terms & Conditions
  • Privacy
  • Your Privacy Choices

© 2025 Travere Therapeutics, Inc. All rights reserved. For U.S. audiences. Total Care Hub®, Travere TotalCare®, and Filspari® are registered trademarks of Travere Therapeutics.  Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.